NCT04439227 2025-10-31Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled
NCT02666950 2019-09-06WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeMayo ClinicPhase 2 Completed3 enrolled 11 charts